US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kairos Pharma, Ltd.

1.66

-0.1100-6.21%

Pre-market: 1.64-0.0236-1.42%07:52 EDT

Volume:81.90K

Turnover:141.51K

Market Cap:5.62M

PE:-0.85

High:1.80

Open:1.76

Low:1.66

Close:1.77

52wk High:13.02

52wk Low:1.51

Shares:3.39M

Float Shares:2.25M

Volume Ratio:0.58

T/O Rate:3.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.9469

EPS(LYR):-2.0691

ROE:-113.96%

ROA:-66.91%

PB:1.34

PE(LYR):-0.80

Loading ...

Overview Company News Filings

Kairos Pharma CEO John Yu Presents at H.C. Wainwright Global Investment Conference

Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday

Benzinga Earnings

Kairos Pharma to Conduct 1-for-7 Reverse Stock Split

MT Newswires Live

Kairos Pharma Announces 1-for-7 Reverse Stock Split

THOMSON REUTERS

Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence

Kairos Pharma Q2 FY26 Net Loss Narrows to $1.39 Million; Revenue Flat at no Revenue

Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12

Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)

Kairos Pharma, Bayer partner on prostate cancer therapy

Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer

THOMSON REUTERS

Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105

Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients

Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105

THOMSON REUTERS

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

THOMSON REUTERS

Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization

Kairos Pharma outlines mid-year oncology pipeline and funding plans

Kairos Pharma issues letter from CEO that recaps year, details plans for 2026

Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate

Kairos Pharma says shareholder letter now available to investors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/KAPA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KAPA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","market":"US","secType":"STK","nameCN":"Kairos Pharma, Ltd.","latestPrice":1.66,"timestamp":1788984000000,"preClose":1.77,"halted":0,"volume":81896,"hourTrading":{"tag":"盘前","latestPrice":1.6364,"preClose":1.66,"latestTime":"07:52 EDT","volume":239,"amount":391.03000319999995,"timestamp":1789041145882,"change":-0.0236,"changeRate":-0.014217,"amplitude":0.099337},"delay":0,"changeRate":-0.06214689265536728,"floatShares":2247529,"shares":3385400,"eps":-1.946945,"marketStatus":"Pre-Mkt","change":-0.11,"latestTime":"09-10 07:56:36 EDT","open":1.76,"high":1.8,"low":1.66,"amount":141508.48331120002,"amplitude":0.079096,"askPrice":1.9,"askSize":30,"bidPrice":1.45,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.946945,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789047000000},"marketStatusCode":1,"adr":0,"listingDate":1717992000000,"exchange":"AMEX","adjPreClose":1.66,"preHourTrading":{"tag":"盘前","latestPrice":1.6364,"preClose":1.66,"latestTime":"07:52 EDT","volume":239,"amount":391.03000319999995,"timestamp":1789041145882,"change":-0.0236,"changeRate":-0.014217,"amplitude":0.099337},"postHourTrading":{"tag":"盘后","latestPrice":1.72,"preClose":1.66,"latestTime":"19:30 EDT","volume":980,"amount":1664.4403,"timestamp":1788996607555,"change":0.06,"changeRate":0.036145,"amplitude":0.036145},"volumeRatio":0.5751172063669734},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KAPA\",,,,,undefined,":{"symbol":"KAPA","floatShares":2247529,"roa":"-66.91%","roe":"-113.96%","lyrEps":-2.069102,"volumeRatio":0.5751172063669734,"shares":3385400,"dividePrice":0,"high":1.8,"amplitude":0.079096,"preClose":1.77,"low":1.66,"week52Low":1.51,"pbRate":"1.34","week52High":13.0207,"institutionHeld":0,"latestPrice":1.66,"committee":0.538462,"eps":-1.946945,"divideRate":0,"volume":81896,"delay":0,"ttmEps":-1.946945,"open":1.76,"prevYearClose":4.97,"prevWeekClose":1.84,"prevMonthClose":1.68,"prevQuarterClose":2.6859,"fiveDayClose":1.65,"twentyDayClose":2.5438,"sixtyDayClose":3.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KAPA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-09-01","symbol":"KAPA","defaultRemindTime":1788269400000,"type":"split","dateTimestamp":1788235200000,"forFactor":7,"toFactor":1,"ratio":7}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KAPA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KAPA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KAPA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KAPA","date":"2026-09-09","current":-0.852618,"percent":0.983838,"low":-25.607053,"twenty":-6.887139,"median":-3.842946,"eighty":-2.293968,"high":-0.921385,"avg":-4.575187,"sd":3.031573,"marketCap":5991828},"quantilePoints":[{"date":"2024-09-13","current":-25.607053,"twenty":-25.607053,"median":-25.607053,"eighty":-25.607053,"marketCap":51367748},{"date":"2024-09-20","current":-14.59602,"twenty":-25.607053,"median":-16.196461,"eighty":-14.724055,"marketCap":29279616},{"date":"2024-09-27","current":-10.594918,"twenty":-16.644584,"median":-14.59602,"eighty":-12.803526,"marketCap":21253405},{"date":"2024-10-04","current":-8.706398,"twenty":-15.748337,"median":-12.835535,"eighty":-9.858715,"marketCap":17465034},{"date":"2024-10-11","current":-9.410592,"twenty":-14.724055,"median":-10.594918,"eighty":-8.706398,"marketCap":18877647},{"date":"2024-10-18","current":-9.410592,"twenty":-14.59602,"median":-9.890724,"eighty":-9.026486,"marketCap":18877647},{"date":"2024-10-25","current":-9.602645,"twenty":-14.019861,"median":-9.73068,"eighty":-9.026486,"marketCap":19262905},{"date":"2024-10-31","current":-8.64238,"twenty":-13.098007,"median":-9.602645,"eighty":-8.947104,"marketCap":17336614},{"date":"2024-11-08","current":-8.770415,"twenty":-12.81633,"median":-9.464686,"eighty":-8.64238,"marketCap":17593453},{"date":"2024-11-15","current":-13.158824,"twenty":-13.152678,"median":-9.474609,"eighty":-8.64238,"marketCap":26396601},{"date":"2024-11-22","current":-7.030345,"twenty":-12.924264,"median":-9.410592,"eighty":-8.578362,"marketCap":19270177},{"date":"2024-11-29","current":-7.217821,"twenty":-12.829133,"median":-9.282556,"eighty":-8.469532,"marketCap":19784048},{"date":"2024-12-06","current":-6.608525,"twenty":-12.265778,"median":-9.026486,"eighty":-7.967725,"marketCap":18113966},{"date":"2024-12-13","current":-8.061463,"twenty":-11.119862,"median":-8.738406,"eighty":-7.667763,"marketCap":22096470},{"date":"2024-12-20","current":-7.920856,"twenty":-10.268428,"median":-8.706398,"eighty":-7.780249,"marketCap":21711066},{"date":"2024-12-27","current":-7.827118,"twenty":-9.999554,"median":-8.64238,"eighty":-7.780249,"marketCap":21454130},{"date":"2025-01-03","current":-7.170953,"twenty":-9.909929,"median":-8.578362,"eighty":-7.46154,"marketCap":19655581},{"date":"2025-01-10","current":-4.827504,"twenty":-9.858715,"median":-8.578362,"eighty":-7.311559,"marketCap":13232188},{"date":"2025-01-17","current":-8.295808,"twenty":-9.858715,"median":-8.530349,"eighty":-7.261949,"marketCap":22738809},{"date":"2025-01-24","current":-7.311559,"twenty":-9.756287,"median":-8.373067,"eighty":-7.264142,"marketCap":20040984},{"date":"2025-01-31","current":-6.936607,"twenty":-9.73068,"median":-8.108332,"eighty":-7.170953,"marketCap":19013241},{"date":"2025-02-07","current":-6.749132,"twenty":-9.628252,"median":-8.036517,"eighty":-7.161579,"marketCap":18499370},{"date":"2025-02-14","current":-6.796001,"twenty":-9.602645,"median":-7.967725,"eighty":-7.030345,"marketCap":18627838},{"date":"2025-02-21","current":-6.233573,"twenty":-9.526207,"median":-7.967725,"eighty":-7.030345,"marketCap":17086224},{"date":"2025-02-28","current":-5.671145,"twenty":-9.474865,"median":-7.897422,"eighty":-6.869431,"marketCap":15544609},{"date":"2025-03-07","current":-5.198227,"twenty":-9.462702,"median":-7.803684,"eighty":-6.730384,"marketCap":14248340},{"date":"2025-03-14","current":-4.773372,"twenty":-9.428261,"median":-7.780249,"eighty":-6.44917,"marketCap":13083812},{"date":"2025-03-21","current":-4.898329,"twenty":-9.410592,"median":-7.639642,"eighty":-6.289816,"marketCap":13426320},{"date":"2025-03-28","current":-4.848346,"twenty":-9.33377,"median":-7.452166,"eighty":-6.092966,"marketCap":13289317},{"date":"2025-04-04","current":-4.698397,"twenty":-9.282556,"median":-7.358428,"eighty":-5.577408,"marketCap":12878307},{"date":"2025-04-11","current":-4.948312,"twenty":-9.244146,"median":-7.311559,"eighty":-5.297393,"marketCap":13563323},{"date":"2025-04-17","current":-4.775903,"twenty":-9.141718,"median":-7.263319,"eighty":-5.121191,"marketCap":12431676},{"date":"2025-04-25","current":-5.470376,"twenty":-9.018804,"median":-7.217821,"eighty":-5.172643,"marketCap":14239390},{"date":"2025-05-02","current":-5.034285,"twenty":-8.912535,"median":-7.170953,"eighty":-5.172643,"marketCap":13104245},{"date":"2025-05-09","current":-4.841892,"twenty":-8.744808,"median":-7.124084,"eighty":-5.140524,"marketCap":12603446},{"date":"2025-05-16","current":-2.898471,"twenty":-8.706398,"median":-7.030345,"eighty":-5.053706,"marketCap":10266383},{"date":"2025-05-23","current":-2.643971,"twenty":-8.706398,"median":-7.030345,"eighty":-4.968305,"marketCap":9364944},{"date":"2025-05-30","current":-2.626341,"twenty":-8.693594,"median":-6.936607,"eighty":-4.902727,"marketCap":9302501},{"date":"2025-06-06","current":-2.390394,"twenty":-8.64238,"median":-6.865004,"eighty":-4.843183,"marketCap":8466776},{"date":"2025-06-13","current":-2.711492,"twenty":-8.629576,"median":-6.796001,"eighty":-4.780395,"marketCap":9604104},{"date":"2025-06-20","current":-2.911286,"twenty":-8.578362,"median":-6.702263,"eighty":-4.758377,"marketCap":10311775},{"date":"2025-06-27","current":-3.282332,"twenty":-8.578362,"median":-6.467918,"eighty":-4.698397,"marketCap":11626021},{"date":"2025-07-03","current":-3.096809,"twenty":-8.578362,"median":-6.421049,"eighty":-4.598431,"marketCap":10968898},{"date":"2025-07-11","current":-3.382229,"twenty":-8.578362,"median":-6.327311,"eighty":-4.315248,"marketCap":11979856},{"date":"2025-07-18","current":-4.852143,"twenty":-8.578362,"median":-6.210138,"eighty":-4.078861,"marketCap":17186292},{"date":"2025-07-25","current":-4.424013,"twenty":-8.501541,"median":-6.156578,"eighty":-4.315248,"marketCap":15669854},{"date":"2025-08-01","current":-4.281779,"twenty":-8.456729,"median":-5.830571,"eighty":-4.144691,"marketCap":15166060},{"date":"2025-08-08","current":-4.566723,"twenty":-8.326712,"median":-5.698056,"eighty":-4.256377,"marketCap":16175333},{"date":"2025-08-15","current":-5.460044,"twenty":-8.265781,"median":-5.577408,"eighty":-4.144691,"marketCap":25722268},{"date":"2025-08-22","current":-5.151816,"twenty":-8.175816,"median":-5.56016,"eighty":-4.256377,"marketCap":24270205},{"date":"2025-08-29","current":-5.548109,"twenty":-8.117706,"median":-5.504045,"eighty":-4.350727,"marketCap":26137143},{"date":"2025-09-05","current":-6.825055,"twenty":-8.080211,"median":-5.554134,"eighty":-4.371339,"marketCap":32152835},{"date":"2025-09-12","current":-7.925871,"twenty":-8.146034,"median":-5.577408,"eighty":-4.403843,"marketCap":37338777},{"date":"2025-09-19","current":-5.90037,"twenty":-8.123413,"median":-5.684601,"eighty":-4.424013,"marketCap":27796645},{"date":"2025-09-26","current":-5.019718,"twenty":-8.080211,"median":-5.577408,"eighty":-4.452555,"marketCap":23647892},{"date":"2025-10-03","current":-5.063751,"twenty":-8.031527,"median":-5.554134,"eighty":-4.485854,"marketCap":23855329},{"date":"2025-10-10","current":-5.812305,"twenty":-7.985263,"median":-5.56016,"eighty":-4.525921,"marketCap":27381769},{"date":"2025-10-17","current":-5.151816,"twenty":-7.967725,"median":-5.531688,"eighty":-4.55855,"marketCap":24270205},{"date":"2025-10-24","current":-4.799555,"twenty":-7.967725,"median":-5.492822,"eighty":-4.58125,"marketCap":22610703},{"date":"2025-10-31","current":-5.019718,"twenty":-7.967725,"median":-5.46521,"eighty":-4.595432,"marketCap":23647892},{"date":"2025-11-07","current":-3.830837,"twenty":-7.967725,"median":-5.399832,"eighty":-4.525921,"marketCap":18047075},{"date":"2025-11-14","current":-3.48298,"twenty":-7.942613,"median":-5.371979,"eighty":-4.424013,"marketCap":16408318},{"date":"2025-11-21","current":-2.82458,"twenty":-7.922862,"median":-5.327946,"eighty":-4.230974,"marketCap":14298023},{"date":"2025-11-28","current":-3.42923,"twenty":-7.902108,"median":-5.296194,"eighty":-4.097795,"marketCap":17358761},{"date":"2025-12-05","current":-3.740193,"twenty":-7.855239,"median":-5.283914,"eighty":-3.903739,"marketCap":18932856},{"date":"2025-12-12","current":-3.331745,"twenty":-7.817744,"median":-5.203591,"eighty":-3.780288,"marketCap":16865295},{"date":"2025-12-19","current":-3.187781,"twenty":-7.79431,"median":-5.197038,"eighty":-3.655562,"marketCap":16136548},{"date":"2025-12-26","current":-3.052866,"twenty":-7.780249,"median":-5.190491,"eighty":-3.531486,"marketCap":15453608},{"date":"2026-01-02","current":-2.920419,"twenty":-7.780249,"median":-5.153702,"eighty":-3.48298,"marketCap":14783160},{"date":"2026-01-09","current":-3.989868,"twenty":-7.780249,"median":-5.151816,"eighty":-3.42923,"marketCap":20196712},{"date":"2026-01-16","current":-3.660807,"twenty":-7.780249,"median":-5.14469,"eighty":-3.42923,"marketCap":18531004},{"date":"2026-01-23","current":-3.208347,"twenty":-7.755842,"median":-5.119133,"eighty":-3.42923,"marketCap":16240655},{"date":"2026-01-30","current":-2.734499,"twenty":-7.661662,"median":-5.098261,"eighty":-3.381278,"marketCap":13842035},{"date":"2026-02-06","current":-2.426827,"twenty":-7.586816,"median":-5.063751,"eighty":-3.364521,"marketCap":12284598},{"date":"2026-02-13","current":-2.442869,"twenty":-7.51395,"median":-5.063751,"eighty":-3.27767,"marketCap":12365801},{"date":"2026-02-20","current":-2.303429,"twenty":-7.470914,"median":-5.048278,"eighty":-3.204892,"marketCap":11659957},{"date":"2026-02-27","current":-2.271757,"twenty":-7.452166,"median":-5.027001,"eighty":-3.156747,"marketCap":11499633},{"date":"2026-03-06","current":-2.698302,"twenty":-7.424045,"median":-5.019718,"eighty":-3.093003,"marketCap":13658807},{"date":"2026-03-13","current":-2.46796,"twenty":-7.400606,"median":-4.98699,"eighty":-3.049512,"marketCap":12492811},{"date":"2026-03-20","current":-2.529659,"twenty":-7.374048,"median":-4.948312,"eighty":-3.027281,"marketCap":12805132},{"date":"2026-03-27","current":-2.419423,"twenty":-7.358428,"median":-4.925987,"eighty":-2.995692,"marketCap":12247119},{"date":"2026-04-02","current":-2.380758,"twenty":-7.33968,"median":-4.899021,"eighty":-2.954226,"marketCap":12051399},{"date":"2026-04-10","current":-2.200475,"twenty":-7.311559,"median":-4.852143,"eighty":-2.923199,"marketCap":11985988},{"date":"2026-04-17","current":-2.403699,"twenty":-7.292811,"median":-4.845967,"eighty":-2.911648,"marketCap":13092947},{"date":"2026-04-24","current":-2.628935,"twenty":-7.263594,"median":-4.843588,"eighty":-2.858198,"marketCap":14319809},{"date":"2026-05-01","current":-2.220915,"twenty":-7.244298,"median":-4.831805,"eighty":-2.782532,"marketCap":12097326},{"date":"2026-05-08","current":-2.180035,"twenty":-7.217821,"median":-4.799555,"eighty":-2.739123,"marketCap":11874650},{"date":"2026-05-15","current":-1.805229,"twenty":-7.199074,"median":-4.787133,"eighty":-2.720186,"marketCap":10540732},{"date":"2026-05-22","current":-2.027078,"twenty":-7.170953,"median":-4.758877,"eighty":-2.696512,"marketCap":11836110},{"date":"2026-05-29","current":-1.932471,"twenty":-7.170953,"median":-4.74838,"eighty":-2.638077,"marketCap":11283701},{"date":"2026-06-05","current":-1.708789,"twenty":-7.161579,"median":-4.699647,"eighty":-2.62783,"marketCap":9977618},{"date":"2026-06-12","current":-1.680187,"twenty":-7.124084,"median":-4.685648,"eighty":-2.591975,"marketCap":9810610},{"date":"2026-06-18","current":-1.675786,"twenty":-7.124084,"median":-4.679404,"eighty":-2.58889,"marketCap":9784917},{"date":"2026-06-26","current":-1.374365,"twenty":-7.089251,"median":-4.661863,"eighty":-2.57116,"marketCap":8024917},{"date":"2026-07-02","current":-1.349796,"twenty":-7.079622,"median":-4.616471,"eighty":-2.529659,"marketCap":7881461},{"date":"2026-07-10","current":-1.356764,"twenty":-7.039719,"median":-4.598431,"eighty":-2.499514,"marketCap":7922143},{"date":"2026-07-17","current":-1.246389,"twenty":-7.030345,"median":-4.556506,"eighty":-2.476269,"marketCap":7277666},{"date":"2026-07-24","current":-1.092378,"twenty":-7.030345,"median":-4.471583,"eighty":-2.464669,"marketCap":6378395},{"date":"2026-07-31","current":-1.099712,"twenty":-7.030345,"median":-4.424013,"eighty":-2.432997,"marketCap":6421218},{"date":"2026-08-07","current":-1.430102,"twenty":-7.030345,"median":-4.370776,"eighty":-2.403935,"marketCap":8350367},{"date":"2026-08-14","current":-1.327826,"twenty":-6.98643,"median":-4.154767,"eighty":-2.384707,"marketCap":7708031},{"date":"2026-08-21","current":-1.204683,"twenty":-6.944825,"median":-4.098893,"eighty":-2.357708,"marketCap":6993186},{"date":"2026-08-28","current":-0.983831,"twenty":-6.936607,"median":-4.005778,"eighty":-2.333263,"marketCap":5711141},{"date":"2026-09-04","current":-0.973869,"twenty":-6.906926,"median":-3.91591,"eighty":-2.299446,"marketCap":5653307},{"date":"2026-09-09","current":-1.032184,"twenty":-6.887139,"median":-3.842946,"eighty":-2.293968,"marketCap":5991828}],"updateTime":1789040799013},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KAPA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666538350","title":"Kairos Pharma CEO John Yu Presents at H.C. Wainwright Global Investment Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538350","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538350?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:00","pubTimestamp":1788955226,"startTime":"0","endTime":"0","summary":"Kairos Pharma CEO John Yu presents at H.C. Wainwright Global Investment ConferenceKairos Pharma will present at the H.C. Wainwright 28th Annual Global Investment Conference on Sept. 14, 2026.Chief exe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL5H5zPS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661225641","title":"Applied Optoelectronics, PDD Holdings And 3 Stocks To Watch Heading Into Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2661225641","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661225641?lang=en_us&edition=fundamental","pubTime":"2026-08-24 14:30","pubTimestamp":1787553057,"startTime":"0","endTime":"0","summary":"U.S. stock futures up, PDD, AAOI, and XPEV to report earnings, KAPA announces reverse stock split, GRRR expected to post earnings after close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/08/61374649/applied-optoelectronics-pdd-holdings-and-3-stocks-to-watch-heading-into-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1769817096.USD","LU0737861772.HKD","GRRR","LU0072462343.USD","LU1956131251.USD","LU1868837565.USD","LU1719994722.HKD","LU0823413660.USD","XPEG","IE00B66KJ199.SGD","LU1064131342.USD","HK0000306685.HKD","LU1046422090.SGD","SG9999014674.SGD","LU0516422952.EUR","BK4553","AAOZ","LU0307460666.USD","LU0315179316.USD","LU0329678170.USD","09868","LU0329678337.USD","BK4558","LU0650527681.SGD","LU0823038988.USD","LU0049112450.USD","LU0417516902.SGD","LU0210526637.USD","SG9999002463.SGD","LU0359202008.SGD","LU1048596156.SGD","LU0502904849.HKD","HK0000306701.USD","LU1880383366.USD","LU0328353924.USD","FDNI","LU1171460220.USD","LU0039217434.USD","BK4504","LU0231483743.USD","LU0140636845.USD","SG9999002562.SGD","LU0594300179.USD","BK4503","BK4505","BK4535","LAZR","LU0370786039.SGD","LU0594300419.USD","LU0823426480.USD","LU1720050803.USD","LU0605514214.HKD","LU0708995583.HKD","LU1981816686.USD","ONLN","DRAG","LU1048588211.SGD","LU0048580855.USD","LU0051755006.USD","BK4220","LU0683595622.HKD","LU0456827905.SGD","LU0588546209.SGD","LU0821914370.USD","AAOG","LU1235295612.USD","BK4509","LU1023057109.AUD","BK4501","AAOI","HK0000320223.HKD","IE00B7SZL793.SGD","BK4555","LU2008162690.USD","LU2211817866.USD","LU2279858448.HKD","LU1808992512.USD","CLIX","BK4548","WISE","KPDD","BK4585","LU0052750758.USD","PDDL","LU0320764599.SGD","LU0117841782.USD","LU0823397285.USD","LU0455707207.USD","HK0000320264.USD","BK4551","LU0516422440.USD","LU0589944569.HKD","LU0871576103.HKD","LU2039709279.SGD","IE00B19Z4B17.USD","AAOX","LU0561508036.HKD","BK4531","LU0259732245.USD","LU2399975544.HKD","LU1242518931.SGD","LU1868837722.USD","SG9999002828.SGD","LU0456846285.SGD","IE0034224299.USD","LU0516423174.USD","LU1242518857.USD","IE00B0JY6N72.USD","LU2242644610.SGD","KWEB","LU0823039010.USD","LU2257852520.SGD","LU0143863198.USD","LU1303224171.USD","XITK","LU1961090484.USD","LU1794554557.SGD","BK4526","LU0359201612.USD","LU0633140560.USD","BK4139","IE00B3M56506.USD","LU0348827113.USD","XPEV","LU0979878070.USD","LU0143863784.USD","LU1770034418.SGD","LU2264538146.SGD","LU1323998911.USD","LU0047713382.USD","LU1251922891.USD","EVS.SI","BK4020","LU1880383440.USD","PDD","LU2087589342.USD","LU0348805143.USD","LU0348788117.USD","LU0359201885.HKD","LU0823413587.USD","LU0823426308.USD","IE0031814852.USD","BK4588","IE0031619046.USD","LU0164865239.USD","LU0823397103.USD","LU0235996351.USD","LU0516423091.SGD","BK4099","BK4122","KAPA","LU0531971595.HKD","LU0633140727.USD","LU1868838027.USD","IE00BGV7N243.SGD","LU0327786744.USD","LU0516422366.SGD","LU1988902786.USD","LU0572944931.SGD","IE00B29SXG58.USD","BK4023","LU1769817179.HKD","LU0878005551.USD","LU2177674079.SGD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661892290","title":"Kairos Pharma to Conduct 1-for-7 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2661892290","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661892290?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:45","pubTimestamp":1787345144,"startTime":"0","endTime":"0","summary":"Kairos Pharma  will implement a one-for-seven reverse stock split of its outstanding shares on Sept. 1, the company said late Friday.The stock split is aimed at reducing the number of outstanding shares and raising the per-share trading price to maintain compliance for continued listing on the NYSE American, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KAPA","KAIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661297419","title":"Kairos Pharma Announces 1-for-7 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2661297419","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661297419?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:30","pubTimestamp":1787344202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nTUA23YLQ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659611809","title":"Kairos Pharma Warns NYSE American Compliance Risks Could Trigger Delisting and Damage Investor Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2659611809","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659611809?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:00","pubTimestamp":1786687253,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. (KAPA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Kairos Pharma, Ltd. faces a significant risk...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-warns-nyse-american-compliance-risks-could-trigger-delisting-and-damage-investor-confidence?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-warns-nyse-american-compliance-risks-could-trigger-delisting-and-damage-investor-confidence?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4107","BK4139","BK4117","KAPA","AFG","KAIR","NYSE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900990","title":"Kairos Pharma Q2 FY26 Net Loss Narrows to $1.39 Million; Revenue Flat at no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900990","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900990?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:18","pubTimestamp":1786565887,"startTime":"0","endTime":"0","summary":"Kairos Pharma Q2 FY26 net loss narrows to $1.39 million; revenue flat at no revenueKairos Pharma posted a Q2 net loss of USD 1.39 million, narrowing from USD 1.42 million a year earlier.Operating loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL13jkg8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654425140","title":"Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12","url":"https://stock-news.laohu8.com/highlight/detail?id=2654425140","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654425140?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:35","pubTimestamp":1785173716,"startTime":"0","endTime":"0","summary":"Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kairos Pharma, Ltd.. The associated price target remains the same w...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-env-105s-emerging-resistance-reversal-profile-and-bayer-collaboration-price-target-maintained-at-12-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/pantginis-reiterates-buy-on-env-105s-emerging-resistance-reversal-profile-and-bayer-collaboration-price-target-maintained-at-12-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAPA","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653722282","title":"Analysts Offer Insights on NA Companies: James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (KAPA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653722282","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653722282?lang=en_us&edition=fundamental","pubTime":"2026-07-24 01:10","pubTimestamp":1784826607,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on James Hardie Industries PLC (JHX) and Kairos Pharma, Ltd. (K...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-james-hardie-industries-plc-jhx-and-kairos-pharma-ltd-kapa-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-james-hardie-industries-plc-jhx-and-kairos-pharma-ltd-kapa-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAIR","BK4011","KAPA","NA","BK4139","JHX","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653153768","title":"Kairos Pharma, Bayer partner on prostate cancer therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2653153768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653153768?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:58","pubTimestamp":1784725105,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) just unveiled an update. On July 16, 2026, Kairos Pharma entered into an investigator-initiated research agreement ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-bayer-partner-on-prostate-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-bayer-partner-on-prostate-cancer-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653750717","title":"Kairos Pharma Partners with Bayer to Test Env-105 with Xofigo in Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653750717","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653750717?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:35","pubTimestamp":1784723719,"startTime":"0","endTime":"0","summary":"Kairos Pharma partners with Bayer to test ENV-105 with Xofigo in metastatic prostate cancerKairos Pharma entered a strategic collaboration with Bayer to test ENV-105 with Bayer’s Xofigo in metastatic ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL9y48WB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653755750","title":"Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance Xofigo Activity in Metastatic Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2653755750","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653755750?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:35","pubTimestamp":1784723702,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nTUAYJVL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463448","title":"Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463448?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118922,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) announced interim safety data from its ongoing Phase 1 clinical trial evaluating ENV-105 in combination with osimertinib in pa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-announces-interim-safety-data-from-phase-1-trial-of-env-105-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","MEDX","HYLG","IDNA","BBC","GDOC","BK4139","KAIR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463982","title":"Kairos Pharma Says Phase 1 Env-105 Plus Tagrisso Trial Shows no Grade 3+ Toxicities in 13 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463982","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463982?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:35","pubTimestamp":1784118907,"startTime":"0","endTime":"0","summary":"Kairos Pharma says Phase 1 ENV-105 plus Tagrisso trial shows no Grade 3+ toxicities in 13 patientsKairos Pharma reported interim Phase 1 safety data for ENV-105 with AstraZeneca’s Tagrisso in EGFR-mut","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL9M2cfC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651463351","title":"Kairos Pharma - no Grade 3 or Higher Adverse Events Observed in 13 Patients Treated with Env-105","url":"https://stock-news.laohu8.com/highlight/detail?id=2651463351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651463351?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651146339","title":"Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of Env-105 in Egfr-mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2651146339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651146339?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nFWN43H0II:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648956752","title":"Kairos Pharma Holds Annual Shareholder Meeting, Approves Reverse Stock Split Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2648956752","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648956752?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:20","pubTimestamp":1782854405,"startTime":"0","endTime":"0","summary":"Kairos Pharma holds annual shareholder meeting, approves reverse stock split authorizationKairos Pharma held its 2026 annual shareholder meeting on June 29, 2026.Shareholders ratified Weinberg & Compa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL3nYwkS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570921","title":"Kairos Pharma outlines mid-year oncology pipeline and funding plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570921","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570921?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:37","pubTimestamp":1780576665,"startTime":"0","endTime":"0","summary":"Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On June 4, 2026, Kairos Pharma issued a mid-year update highlighting a term sheet to ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kairos-pharma-outlines-mid-year-oncology-pipeline-and-funding-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KAIR","KAPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640522157","title":"Kairos Pharma issues letter from CEO that recaps year, details plans for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640522157","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640522157?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:18","pubTimestamp":1780575508,"startTime":"0","endTime":"0","summary":"Kairos Pharma (KAPA) provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to shareholders from CEO John Yu, M.D...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kairos-pharma-issues-letter-from-ceo-that-recaps-year-details-plans-for-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KAPA","KAIR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157333","title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157333","media":"Reuters","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157333?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:15","pubTimestamp":1780575344,"startTime":"0","endTime":"0","summary":"Kairos Pharma signed a term sheet to acquire worldwide rights to CL-741 from privately held Celyn Therapeutics.CL-741 is an orally available, Phase 1-ready type IIb c-MET kinase inhibitor targeting EGFR-mutated NSCLC.Planned Phase 1 initiation in 2026; program also targets esophageal cancer, gastric cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL6xNyb8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Kairos Pharma signs term sheet to acquire worldwide rights to Celyn Therapeutics’ CL-741 cancer drug candidate","news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KAPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640294152","title":"Kairos Pharma says shareholder letter now available to investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2640294152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640294152?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:02","pubTimestamp":1780574538,"startTime":"0","endTime":"0","summary":"Kairos Pharma posted a mid-year 2026 letter to shareholders from CEO John Yu outlining priorities for the rest of the year.Letter highlights a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready oral type IIb c-MET inhibitor.Plan calls for initiating a Phase 1 CL-741 study in EGFR-mutated lung cancer; ENV-105 trials continue in prostate cancer, NSCLC results targeted by Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kairos Pharma Ltd. published the original content used to generate this news brief via Business Wire  on June 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL39tg7Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KAPA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}]}}